Abstract
The patterns by which primary tumors spread to metastatic sites remain poorly understood. Here, we define patterns of metastatic seeding in prostate cancer using a novel injection-based mouse model—EvoCaP (Evolution in Cancer of the Prostate), featuring aggressive metastatic cancer to bone, liver, lungs, and lymph nodes. To define migration histories between primary and metastatic sites, we used our EvoTraceR pipeline to track distinct tumor clones containing recordable barcodes. We detected widespread intratumoral heterogeneity from the primary tumor in metastatic seeding, with few clonal populations instigating most migration. Metastasis-to-metastasis seeding was uncommon, as most cells remained confined within the tissue. Migration patterns in our model were congruent with human prostate cancer seeding topologies. Our findings support the view of metastatic prostate cancer as a systemic disease driven by waves of aggressive clones expanding their niche, infrequently overcoming constraints that otherwise keep them confined in the primary or metastatic site. Significance: Defining the kinetics of prostate cancer metastasis is critical for developing novel therapeutic strategies. This study uses CRISPR/Cas9-based barcoding technology to accurately define tumor clonal patterns and routes of migration in a novel somatically engineered mouse model (EvoCaP) that recapitulates human prostate cancer using an in-house developed analytical pipeline (EvoTraceR).
Funding Information
  • National Cancer Institute (R01-CA272466)
  • National Cancer Institute (NIH 2018 P50 CA)
  • American Cancer Society (Research Scholar Grant)
  • Department of Defense Education Activity (W81XWH-22-1-0068)
  • National Institutes of Health (R35-GM127070)
  • National Cancer Institute (T32CA203702)
  • National Institutes of Health (5T32GM141949)
  • National Institutes of Health (1T32GM141949)
  • Starr Foundation (Centennial Scholarship)
  • Cancer Research UK (22790)
  • Fondazione AIRC per la ricerca sul cancro ETS (22790)